Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
treating patients with severe to very severe alopecia areata, an autoimmune disorder characterized by patchy hair loss. Alopecia areata is a condition affecting nearly 700,000 of the American population currently. The disease has a tremendous adverse impact on the quality of life of the patients. The double-blind, placebo-controlled, global phase IIb study will evaluate the safety and efficacy of rezpeg in patients with severe to very severe alopecia areata over a period of 36-week induction treatment. The study will compare two different dosing regimens of rezpeg versus placebo in 84 participants during the induction period. The primary efficacy endpoint of the study is the mean percent improvement in the Severity of Alopecia Tool (SALT) at week 36 of treatment. Shares of Nektar have plunged 33.5% in the past year compared with the industry's decline of 2.4%. Image Source: Zacks Investment Research Nektar is also developing rezpeg for various other types of autoimmune and
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test [Seeking Alpha]Seeking Alpha
- Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferencePR Newswire
- Nektar Therapeutics (NASDAQ: NKTR) had its price target raised by analysts at Jefferies Financial Group Inc. from $0.50 to $1.00. They now have a "hold" rating on the stock.MarketBeat
NKTR
Earnings
- 3/4/24 - Miss
NKTR
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/17/24 - Form 8-K
- NKTR's page on the SEC website